Місце інгібіторів протонної помпи у лікуванні хронічного панкреатиту. Огляд та власні спостереження
Ключові слова:
хронічний панкреатит, зовнішньосекреторна недостатність підшлункової залози, патогенез, лікування, інгібітори протонної помпАнотація
Проаналізовано дані літератури щодо ролі кислотопродукувальної функції шлунка в панкреатичній секреції. Пояснено показання до призначення інгібіторів протонної помпи при хронічному панкреатиті на підставі міжнародних рекомендацій і результатів доказових досліджень. Описано переваги пантопразолу («Нольпаза»). Як приклад ефективності «Нольпази» при хронічному панкреатиті наведено власне клінічне спостереження пацієнтки з кальцифікуючим панкреатитом, вираженим больовим синдромом і тяжкою зовнішньосекреторною недостатністю підшлункової залози.Посилання
Balantsova EL. Comparative evaluation of the effectiveness of two treatment options for patients with chronic pancreatitis and erosive and ulcerative lesions of the gastroduodenal zone on the background of excessive body mass. Herald of urgent and reconstructive surgery. 2011;Т. 12, вып. 1:48-51.
Gubergrits NB, Kriuk MA. Experience of pathogenetically substantiated therapy of patients with chronic pancreatitis combined with gastroesophageal reflux disease and obesity. Modern Gastroenterology. 2008;1:45-54.
Gubergits NB, Fomenko PG, Golubova OA, Byelyayeva NV. Rational choice of proton pump inhibitor for the treatment of chronic pancreatitis combined with drug-induced lesions of the liver. Modern Gastroenterology. 2016;1:63-81.
Zak MY, Pasyeshvili LM, Knysh MY. Course features and choice of chronic gastritis therapy upon selective NSAIDs for osteoarthritis. Modern Gastroenterology. 2014;6:121-128.
Korot’ko G. F. Postprandial pancreatic secretion. — Krasnodar: EDVI, 2017:115.
Korot’ko G. F. Pancreatic secretion. — Krasnodar: Publishing house of Kuban State Med. Un-ty, 2005:312.
Kucheryavy YA. Experience of esomeprazole inclusion in complex therapy of exacerbation of chronic pancreatitis. Clin. Perspect. Gastroenterol., Hepatol. 2005;6:35-41.
Kucheryavy YA. Chronic pancreatitis as an acid-dependent disease. Experim. & Clin. Gastroenterol. 2010;9:107-115.
Loginov AF. Opportunities of using pantoprazole in therapy of gastroesophageal reflux disease. Farmateka. 2012;2:29-33.
Maev IV, Burkov SG, Yurenev GL. Gastroesophageal reflux disease and associated pathology. М.: Litterra, 2014:352.
Maev IV, Kucheryavy YA. Gastric acid formation and chronic pancreatitis: how strong is the relationship?. Rus. J. Gastroenterol., Hepatol., Coloproctol. 2008;3:4-14.
Maev IV, Samsonov AA, Andreev DN. Gastric Diseases. М.: Geotar-Media, 2015:976.
Wise thoughts on medicine and healing / Ed. Y. S. Tsimmermann. М.: Geotar-Media, 2015:256.
Starostin BD. Combined therapy of chronic pancreatitis (double-blind placebo-controlled pilot study). Experim. & Clin. Gastroenterol. 2003;3:58-65.
Tkach SM, Kuzenko YG, Marusanich BN. Cytochrome p450 and metabolism of proton pump inhibitors. Modern Gastroenterology. 2006;1:50-55.
Tkach SM, Sizenko AK. Efficiency of proton pump inhibitors in the prevention and treatment of NSAIDs-gastropathies from the perspective of evidence-based medicine. Ukr. Ther. J. 2012;1:93-102.
Fadeenko GD, Gridnev AE. Gastroesophageal reflux disease: esophageal, extra-esophageal manifestations and comorbidity. К.: Library «Health of Ukraine», 2014:376.
Tsimmermann YS. Gastroenterology / Y. S. Tsimmermann. М.: Geotar-Media, 2015:816.
Antigua AD, Tran J, Lemon SJ, Zhang Y. challenges of administering pancrelipase in pancreatitis patients. J Am Coll Nutr. 2016;35(4):334-338.
Brain-gut axis in pancreatic secretion and appetite control Konturek SJ, Pepera J, Zabielski K et al.. J Physiol Pharmacol. 2003;54:293-317.
Cai J, Zhou W, Luo HS, Peng LV. Effect of proton pump inhibitor on amylase release from isolated pancreatic acini. In Vitro Cell Dev Biol Anim. 2007;43(1):25-27.
Carroccio A, Pardo F, Montalto G et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. Dig Dis Sci. 1992;37:1441-1446.
Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-133.
Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M et al. Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut. 2006;55:1056-1057.
Geus WP, Eddes EH, Gielkens HA et al. Post-prandial intragastric and duodenal acidity are increased in patients with chronic pancreatitis. Aliment Pharmacol Ther. 1999;13:937-943.
Hackert T, Tudor S, Felix K et al. Effects of pantoprazole in experimental acute pancreatitis. Life Sci. 2010;87, N 17-18:551-557.
Hauge T, Persson J, Sjolund K. Neuropeptides in the duodenal mucosa of chronic alcoholic heavy drinkers. Alcohol. 2001;36:213-218.
Lankisch PG, Lembcke B, Goke B et al. Therapy of pancreatogenic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage?. Z Gastroenterol. 1986;24:753-757.
Li JP, Chang TM, Wagner D et al. Pancreatic phospholipase A2 from the small intestine is a secretin-releasing factor in rats. Am J Physiol Gastrointest Liver Physiol. 2001;281:526-532.
Lin HC, Hsiao YT, Lin HL et al. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study. Medicine (Baltimore). 2016;95, N 28. e4195.
Lohr JM, Dominguez-Munoz E, Rosendahl J et al. United European Gastroenterology evidence based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J. 2017;5(2):1-47.
Mullin JM, Gabello M, Murray LJ et al. Proton pump inhbitors: actions and reactions. Drug Disc Today. 2009;14, N 13-14:647-660.
Murata A, Ohtani M, Muramatsu K, Matsuda S. Effects of proton pump inhibitor on outcomes of patients with severe acute pancreatitis based on a national administrative database. Pancreatol. 2015;15(5):491-496.
Pancreatitis: medical and surgical management / Ed. by D. B. Adams et al. Chichester: Wiley Blackwell, 2017:326.
Pilotto A, Franceschi M, Leanardo G. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13(33):4467-4472.
Pujahari AK. A novel method for pain relief in chronic pancreatitis: an old drug in a new pack: a controlled study. Indian J Surg. 2017;79(6):549-554.
Sachs G. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors. Drugs of Today. 2003;39, suppl. A:11-14.
Sander-Struckmeier S, Beckmann K, Janssen-van Solingen G et al. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON (R)) in patients with pancreatic exocrine insufficiency. Pancreas. 2013;42:983-989.
Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases — A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27-37.
Thiagarajan P, Jankowski JA. Aspirin and NSAIDs; benefits and harms for the gut. Best Pract Res Clin Gastroenterol. 2012;26:197-206.
Tosetti C, Nanni I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther. 2017;8(3):180-185.
Wang J, Barbuskaite D, Tozzi M et al. Proton pump inhibitors inhibit pancreatic secretion: Role of gastric and non-gastric H+/K+-ATPases. PLoS One. 2015;10, N 5. e0126432.
Yoo JH, Kwon CI, Yoo KH et al. Effect of proton pump inhibitor in patients with acute pancreatitis — pilot study. Korean J Gastroenterol. 2012;60(6):362-367.
Youssef SS, Iskandar SB, Scruggs J, Roy TM. Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther. 2005;43(12):558-561.
